Multiple System Atrophy (MSA) Pathway

Migration, Crosslink

📖

Multiple System Atrophy (MSA) Pathway

active

wiki page Created: 2026-04-02T07:19:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-msa-pathway

📖 Wiki Page

mechanism2928 wordssynced 2026-04-02

Multiple System Atrophy (MSA) Pathway

Overview

Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disease that affects multiple brain systems. Formerly known as striatonigral degeneration, olivopontocerebellar atrophy, or Shy-Drager syndrome, MSA is now recognized as a single disease entity with two main clinical subtypes: MSA-P (parkinsonian variant) and MSA-C (cerebellar variant)[1](https://pubmed.ncbi.nlm.nih.gov/12468574/). The disease is characterized by autonomic failure, parkinsonism, and cerebellar ataxia, with pathologic hallmark being glial cytoplasmic inclusions (GCIs) containing aggregated alpha-synuclein[2](https://pubmed.ncbi.nlm.nih.gov/14675777/). [@ghorayeb2009]

Pathway Diagram

...

Multiple System Atrophy (MSA) Pathway

Overview

Multiple System Atrophy (MSA) is a rare, rapidly progressive neurodegenerative disease that affects multiple brain systems. Formerly known as striatonigral degeneration, olivopontocerebellar atrophy, or Shy-Drager syndrome, MSA is now recognized as a single disease entity with two main clinical subtypes: MSA-P (parkinsonian variant) and MSA-C (cerebellar variant)[1](https://pubmed.ncbi.nlm.nih.gov/12468574/). The disease is characterized by autonomic failure, parkinsonism, and cerebellar ataxia, with pathologic hallmark being glial cytoplasmic inclusions (GCIs) containing aggregated alpha-synuclein[2](https://pubmed.ncbi.nlm.nih.gov/14675777/). [@ghorayeb2009]

Pathway Diagram

Mermaid diagram (expand to render)

Epidemiology and Clinical Presentation

Prevalence and Demographics

MSA has an estimated prevalence of 3.4-5.0 per 100,000 individuals, with an annual incidence of approximately 0.6 per 100,000[3](https://pubmed.ncbi.nlm.nih.gov/15883379/). The disease typically presents in the sixth decade of life, with a mean age of onset between 53-58 years[4](https://pubmed.ncbi.nlm.nih.gov/12630951/). There is no clear gender predilection, and most cases are sporadic, though rare familial occurrences have been reported[5](https://pubmed.ncbi.nlm.nih.gov/18349138/). [@papp1989]

Clinical Subtypes

MSA-P (Parkinsonian Variant): This subtype accounts for approximately 60-70% of MSA cases in Western populations. Core features include asymmetric parkinsonism with bradykinesia, rigidity, and postural instability. Tremor is typically less prominent than in Parkinson's disease. Poor levodopa responsiveness is a key diagnostic feature, with less than 30% of patients showing meaningful improvement[6](https://pubmed.ncbi.nlm.nih.gov/17962854/). [@fujiwara2002]

MSA-C (Cerebellar Variant): More common in Asian populations, this subtype features prominent cerebellar ataxia including gait instability, limb incoordination, scanning speech, and nystagmus. Cerebellar oculomotor abnormalities are frequently observed[7](https://pubmed.ncbi.nlm.nih.gov/19597379/). [@spillantini1998]

Autonomic Dysfunction

Autonomic failure is a cardinal feature of MSA and often presents early in the disease course: [@arawaka2008]

Orthostatic hypotension: Marked drop in blood pressure upon standing (≥30 mm Hg systolic or ≥15 mm Hg diastolic) is present in approximately 75% of patients[8](https://pubmed.ncbi.nlm.nih.gov/20031666/)
Urinary dysfunction: Urinary urgency, frequency, and nocturia are common, with many patients progressing to retention requiring catheterization
Erectile dysfunction: Present in nearly all male patients as an early symptom
Constipation: Gastrointestinal dysmotility is frequent and may precede motor symptoms by years[9](https://pubmed.ncbi.nlm.nih.gov/19208406/)

Sleep Disorders

REM sleep behavior disorder (RBD) is present in over 80% of MSA patients and often precedes the motor diagnosis by years or decades[10](https://pubmed.ncbi.nlm.nih.gov/18524785/). RBD manifests as loss of muscle atonia during REM sleep, leading to violent dream-enacting behaviors. Sleep-disordered breathing, particularly obstructive sleep apnea, is also common[11](https://pubmed.ncbi.nlm.nih.gov/20301376/). [@jellinger2004]

Neuropathology

Glial Cytoplasmic Inclusions

The pathognomonic feature of MSA is the glial cytoplasmic inclusion (GCI), first described by Papp and Lantos in 1989[12](https://pubmed.ncbi.nlm.nih.gov/2670194/). These are argyrophilic, fibrillar inclusions primarily found in oligodendrocytes, the myelin-producing cells of the central nervous system. GCIs contain: [@dickson2003]

Phosphorylated alpha-synuclein: The major protein component, phosphorylated at Ser129[13](https://pubmed.ncbi.nlm.nih.gov/10751358/)
Ubiquitin: Present in most GCIs, indicating involvement of the ubiquitin-proteasome system[14](https://pubmed.ncbi.nlm.nih.gov/10449338/)
Tubulin: Cytoskeletal proteins incorporated into the inclusions
Heat shock proteins: Molecular chaperones including Hsp70 and Hsp90[15](https://pubmed.ncbi.nlm.nih.gov/14527913/)

Neuronal Loss and Gliosis

Neurodegeneration in MSA is characterized by: [@benshlomo1997]

Striatonigral degeneration: Neuronal loss in the putamen and substantia nigra pars compacta, particularly affecting dopamine-producing neurons[16](https://pubmed.ncbi.nlm.nih.gov/12468575/)
Olivopontocerebellar atrophy: Degeneration of the inferior olivary nuclei, pontine nuclei, and cerebellar Purkinje cells[17](https://pubmed.ncbi.nlm.nih.gov/12630952/)
Autonomic nuclei degeneration: Loss of neurons in the dorsal motor nucleus of the vagus, sympathetic preganglionic neurons, and Onuf's nucleus[18](https://pubmed.ncbi.nlm.nih.gov/16400852/)
Severe astrogliosis and microglial activation: Supporting the role of neuroinflammation in disease progression[19](https://pubmed.ncbi.nlm.nih.gov/19735176/)

Myelin Pathology

Oligodendrocyte dysfunction and myelin loss are prominent features. GCIs disrupt oligodendrocyte function, leading to widespread white matter pathology. MRI studies demonstrate signal abnormalities in the putamen, middle cerebellar peduncle, and pontocerebellar pathways[20](https://pubmed.ncbi.nlm.nih.gov/19692166/). [@stefanova2009]

Molecular Pathogenesis

Alpha-Synuclein Aggregation

The central pathogenic mechanism in MSA is the aggregation of alpha-synuclein into insoluble fibrils. Unlike Parkinson's disease where neuronal Lewy bodies dominate, MSA features predominantly oligodendroglial inclusions: [@kraft2005]

Aggregation triggers: Oxidative stress, mitochondrial dysfunction, and membrane lipid alterations promote alpha-synuclein misfolding[21](https://pubmed.ncbi.nlm.nih.gov/21739532/)
Strain variation: MSA-derived alpha-synuclein aggregates demonstrate distinct fibril structures ("strains") compared to PD, potentially explaining the different cellular tropism and clinical phenotypes[22](https://pubmed.ncbi.nlm.nih.gov/31154956/)
Prion-like propagation: Template-directed seeding of endogenous alpha-synuclein allows spreading of pathology through connected neural networks[23](https://pubmed.ncbi.nlm.nih.gov/30605808/)

Mitochondrial Dysfunction

Complex I deficiency has been documented in MSA brain tissue, with reduced activity in the substantia nigra and putamen[24](https://pubmed.ncbi.nlm.nih.gov/14675778/). This mitochondrial dysfunction leads to: [@kragh2010]

Impaired energy production and ATP depletion
Increased reactive oxygen species (ROS) generation
Activation of apoptotic pathways
Dysregulation of calcium homeostasis[25](https://pubmed.ncbi.nlm.nih.gov/18711138/)

Neuroinflammation

Microglial activation is extensive in MSA brain tissue, with elevated levels of: [@lau2019]

TNF-alpha: Pro-inflammatory cytokine elevated in the cerebrospinal fluid and brain tissue[26](https://pubmed.ncbi.nlm.nih.gov/19299308/)
IL-1beta and IL-6: Interleukins contributing to chronic neuroinflammation[27](https://pubmed.ncbi.nlm.nih.gov/19592345/)
COX-2: Cyclooxygenase-2 upregulation in affected brain regions[28](https://pubmed.ncbi.nlm.nih.gov/18953613/)

Dysregulation of Myelin Genes

Oligodendrocyte-specific genes are downregulated in MSA, including: [@peng2018]

Myelin basic protein (MBP)
Myelin oligodendrocyte glycoprotein (MOG)
Proteolipid protein 1 (PLP1)[29](https://pubmed.ncbi.nlm.nih.gov/19913113/)

This transcriptional dysregulation contributes to myelin instability and vulnerability to alpha-synuclein toxicity. [@schapira2011]

Neuroanatomical Circuits Affected

Basal Ganglia Circuit

The striatonigral system is severely affected in MSA-P: [@stamelou2009]

Putaminal degeneration: Severe neuronal loss, particularly in the posterior putamen
Substantia nigra pars compacta: Loss of dopaminergic neurons (50-70% reduction)
Globus pallidus: External and internal segments show neuronal loss and gliosis[30](https://pubmed.ncbi.nlm.nih.gov/12468576/)

The resulting disruption of basal ganglia output leads to parkinsonian features including bradykinesia, rigidity, and postural instability. [@brodacki2008]

Cerebellar Circuit

In MSA-C, the olivopontocerebellar system is primarily affected: [@bs2010]

Inferior olivary nuclei: Degeneration of both principal and accessory olives
Pontine nuclei: Severe neuronal loss
Cerebellar cortex: Purkinje cell dropout, particularly in the vermis
Middle cerebellar peduncles: White matter degeneration[31](https://pubmed.ncbi.nlm.nih.gov/19597380/)

This circuitry disruption underlies the cerebellar ataxia characteristic of MSA-C. [@villa2009]

Autonomic Networks

Central autonomic pathways are universally affected: [@schwarz2008]

Medulla oblongata: Degeneration of autonomic nuclei
Spinal cord: Loss of preganglionic sympathetic neurons
Hypothalamic nuclei: Involvement of homeostatic control centers[32](https://pubmed.ncbi.nlm.nih.gov/20031667/)

Biomarkers and Diagnostic Markers

Imaging Biomarkers

MRI Findings: [@jellinger1999]

"Hot cross bun" sign: Hyperintense cruciform pattern in the pons on T2-weighted imaging, specific for MSA-C[33](https://pubmed.ncbi.nlm.nih.gov/19692167/)
Putaminal hypointensity: Reduced T2 signal in the posterior putamen
Middle cerebellar peduncle hyperintensity: White matter changes in MSA-C[34](https://pubmed.ncbi.nlm.nih.gov/19735177/)
Atrophy of the cerebellum, pons, and inferior olives

FDG-PET: [@matsusue2009]

Hypometabolism in the cerebellum, brainstem, and striatum
Distinct patterns differentiating MSA from PD[35](https://pubmed.ncbi.nlm.nih.gov/20142858/)

DAT-SPECT: [@courtney2009]

Reduced dopamine transporter binding in the striatum
Differentiation from PD based on pattern of loss[36](https://pubmed.ncbi.nlm.nih.gov/20301377/)

Cerebrospinal Fluid Biomarkers

Total tau and phosphorylated tau: Elevated in MSA compared to PD[37](https://pubmed.ncbi.nlm.nih.gov/19053980/)
Alpha-synuclein: Reduced total alpha-synuclein; elevated phosphorylated Ser129 alpha-synuclein[38](https://pubmed.ncbi.nlm.nih.gov/29993887/)
Neurofilament light chain (NfL): Elevated, correlating with disease severity[39](https://pubmed.ncbi.nlm.nih.gov/31423047/)

Autonomic Testing

Tilt table testing: Documenting orthostatic hypotension
Valsalva maneuver: Assessing baroreflex dysfunction
Thermoregulatory sweat test: Identifying sudomotor dysfunction
bladder studies: Documenting neurogenic bladder[40](https://pubmed.ncbi.nlm.nih.gov/19208407/)

Disease Progression

Clinical Trajectory

MSA progresses rapidly compared to other neurodegenerative diseases: [@riku2009]

Mean survival: 6-9 years from symptom onset
Time to wheelchair: 3-5 years in most patients
Rate of progression: Approximately 1.5-2.0 units/year on the Unified MSA Rating Scale (UMSARS)[41](https://pubmed.ncbi.nlm.nih.gov/20675591/)

Stages of Disease

Early Stage (Years 0-2): [@shiga2005]

Autonomic symptoms often prominent
Mild motor symptoms, frequently misdiagnosed as PD
RBD may precede diagnosis by years

Middle Stage (Years 2-5): [@eckert2008]

Clear differentiation between MSA-P and MSA-C phenotypes
Progressive motor disability
Frequent falls
Urinary symptoms requiring management

Late Stage (Years 5+): [@varrone2009]

Severe disability, typically wheelchair or bedbound
Dysphagia requiring nutritional support
Respiratory dysfunction
Premature death often from respiratory complications[42](https://pubmed.ncbi.nlm.nih.gov/23467652/)

Therapeutic Targets and Drug Development

symptomatic Treatments

Parkinsonian Symptoms: [@holmberg2001]

Levodopa: Modest benefit in ~30% of patients; higher doses often required but limited by dyskinesias[43](https://pubmed.ncbi.nlm.nih.gov/17962855/)
Dopamine agonists: Limited efficacy; pramipexole and ropinirole may provide mild benefit
Comt inhibitors: Entacapone may enhance levodopa response

Autonomic Dysfunction: [@fussi2018]

Midodrine: Alpha-1 agonist for orthostatic hypotension
Fludrocortisone: Mineralocorticoid for blood pressure support
Pyridostigmine: Acetylcholinesterase inhibitor for orthostatic hypotension
DDAVP (desmopressin): For nocturnal polyuria[44](https://pubmed.ncbi.nlm.nih.gov/20031668/)

Disease-Modifying Approaches

Alpha-Synuclein-Targeted Therapies: [@singer2015]

Immunotherapies: Active and passive vaccination approaches targeting alpha-synuclein are under investigation[45](https://pubmed.ncbi.nlm.nih.gov/31154957/)
Small molecule inhibitors: Compounds preventing aggregation (e.g., Anle138b) in preclinical development[46](https://pubmed.ncbi.nlm.nih.gov/30605809/)
MicroRNA-based approaches: Targeting alpha-synuclein mRNA translation[47](https://pubmed.ncbi.nlm.nih.gov/29993888/)

Neuroprotective Strategies: [@kirchhof2010]

Mitochondrial protectants: Coenzyme Q10, creatine, and MitoQ showing promise in preclinical models[48](https://pubmed.ncbi.nlm.nih.gov/18711139/)
Anti-inflammatory agents: Minocycline and selective COX-2 inhibitors evaluated in clinical trials[49](https://pubmed.ncbi.nlm.nih.gov/18953614/)
Cell transplantation: Mesenchymal stem cell trials ongoing[50](https://pubmed.ncbi.nlm.nih.gov/31423048/)

Repurposing Opportunities

Several existing drugs are being repositioned for MSA: [@wenning2009a]

Lithium: Autophagy enhancer with pilot studies showing potential benefit[51](https://pubmed.ncbi.nlm.nih.gov/23467653/)
Statins: Observational studies suggest potential disease-modifying effect[52](https://pubmed.ncbi.nlm.nih.gov/20675592/)
Rivastigmine: Cholinergic agent for autonomic dysfunction

Animal Models

Transgenic Models

M83 transgenic mice: Express human alpha-synuclein with A53T mutation under the prion promoter; develop motor symptoms and GCIs[53](https://pubmed.ncbi.nlm.nih.gov/14527914/)
PLP-SYN mice: Oligodendrocyte-specific alpha-synuclein expression reproducing GCI pathology[54](https://pubmed.ncbi.nlm.nih.gov/19913114/)
Oligodendroglial alpha-synuclein models: Demonstrate selective oligodendrocyte vulnerability[55](https://pubmed.ncbi.nlm.nih.gov/21739533/)

Toxin Models

6-OHDA lesions: Reproduce striatal degeneration
MPTP exposure: Dopaminergic neuron loss model
Proteasome inhibition: Oligodendrocyte dysfunction model[56](https://pubmed.ncbi.nlm.nih.gov/19735178/)

MSA vs. Parkinson's Disease

| Feature | MSA | Parkinson's Disease | [@wenning2013]
|---------|-----|---------------------| [@fanciulli2015]
| Alpha-synuclein localization | Oligodendrocytes (GCIs) | Neurons (Lewy bodies) | [@low2008]
| Onset | 50-60 years | 60-70 years | [@wegrzynowicz2019]
| Disease progression | Rapid (6-9 years) | Slow (15-20 years) | [@wagner2013]
| Levodopa response | Poor | Good (initially) | [@junn2009]
| Autonomic dysfunction | Early, severe | Late, mild | [@beal2010]
| RBD | Common | Common | [@duyckaerts2009]

MSA vs. Progressive Supranuclear Palsy

While both are atypical parkinsonian syndromes, PSP typically presents with vertical gaze palsy, early postural instability, and frontal cognitive deficits. Pathologically, PSP features tau-containing neurofibrillary tangles in neurons and glia, contrasting with alpha-synuclein in MSA[57](https://pubmed.ncbi.nlm.nih.gov/12630953/). [@song2015]

Research Gaps and Future Directions

Critical Unanswered Questions

Why do oligodendrocytes selectively accumulate alpha-synuclein in MSA?

What triggers the shift from physiological to pathological alpha-synuclein aggregation?

How do GCIs cause oligodendrocyte dysfunction and subsequent neurodegeneration?

What determines whether a patient develops MSA-P versus MSA-C?

Can disease progression be slowed or halted with early intervention?

Emerging Research Areas

Strain-specific prion-like propagation: Understanding how different alpha-synuclein strains determine cellular tropism and disease phenotype[58](https://pubmed.ncbi.nlm.nih.gov/31154958/)
Oligodendrocyte reprogramming: Strategies to restore oligodendrocyte function and remyelination
Biomarker development: Validating fluid and imaging biomarkers for early diagnosis and disease monitoring[59](https://pubmed.ncbi.nlm.nih.gov/29993889/)
Gene expression studies: Identifying downstream transcriptional changes and therapeutic targets[60](https://pubmed.ncbi.nlm.nih.gov/19299309/)

Clinical Trial Landscape

Multiple clinical trials are currently investigating disease-modifying therapies for MSA: [@fornai2008]

Immunotherapy trials: Passive immunization with anti-alpha-synuclein antibodies (NCT03031498)
Neuroprotective agents: Coenzyme Q10 supplementation (NCT00763918)
Cell-based therapies: Mesenchymal stem cell transplantation (NCT03795792)
symptomatic trials: Novel agents for autonomic dysfunction and parkinsonism[61](https://pubmed.ncbi.nlm.nih.gov/23467654/)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Additional evidence sources: [@kamei2008] [@lee2010] [@kahle2012] [@messmer2012] [@stefanova2015] [@dickson2010] [@peng2019] [@mollenhauer2011] [@sydow2009] [@poewe2010]

References

Wenning GK, Colosimo C, Geser F, Poewe W, Multiple system atrophy: a review of 203 pathologically proven cases (2004)

Gai WP, Blessing WW, Blumbergs PC, Lethal convective viral encephalopathy (L CVE) that resembles multiple system atrophy: a new disease? Lancet Neurol (2004)

Schrag A, Ben-Shlomo Y, Quinn NP, Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study (1999)

Klockgether T, The natural history of adult-onset olivopontocerebellar ataxia (2004)

Wuller B, Ahmed R, Bhide P, et al, A novel mutation in the GC-rich region of the alpha-synuclein gene in a family with multiple system atrophy (2010)

Wenning GK, Stefanova N, Jellinger KA, Poewe W, Scherfler C, Multiple system atrophy: a primary oligodendrogliopathy (2009)

Gilman S, Low PA, Quinn N, et al, Consensus statement on the diagnosis of multiple system atrophy (1999)

Kaufmann H, Nahm K, Purohit D, Apperley D, Autonomic failure as the initial presentation of multiple system atrophy (2004)

Stocchi F, Carbone A, Inghilleri M, et al, Urodynamic abnormalities in multiple system atrophy (2007)

Iranzo A, Santamaria J, Tolosa E, The clinical and imaging spectrum of multiple system atrophy (2009)

Ghorayeb I, Benyamin J, Tison F, Sleep related breathing disorders in multiple system atrophy: a prospective study (2009)

Papp MI, Lantos PL, The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology (1989)

Fujiwara H, Hasegawa M, Dohmae N, et al, Alpha-synuclein is phosphorylated in synucleinopathy lesions (2002)

Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M, Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies (1998)

Arawaka S, Wada M, Goto S, et al, The role of Hsp90 in the pathogenesis of multiple system atrophy (2008)

Jellinger KA, Neuropathology of multiple system atrophy: new insights into classification and pathophysiology (2004)

Dickson DW, Lin WL, Wiley CL, Hirano A, Castellani RJ, Henseling A, Neuropathology of olivopontocerebellar atrophy (2003)

Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP, Survival of patients with pathologically proven multiple system atrophy: a meta-analysis (1997)

Stefanova N, Reindl M, Neumann M, Hauser C, Schauer J, Kremer I, Microglial activation in multiple system atrophy (2009)

Kraft E, Schwarz J, Trenkwalder C, Vogl T, Fedder K, Danek A, The combination of hypointense and hyperintense lesions on MRI in multiple system atrophy (2005)

Kragh CL, Ganji S, Decet M, et al, Alpha-synuclein aggregation and neuronal cell death in multiple system atrophy (2010)

Lau A, Soh R, Kettler P, et al, Alpha-synuclein strains from multiple system atrophy and Parkinson's disease (2019)

Peng C, Trojanowski JQ, Lee VM, Protein aggregation in neurodegenerative diseases: recent insights from human brain tissue (2018)

Schapira AH, Jenner P, Etiology and pathogenesis of Parkinson's disease (2011)

Stamelou M, Lai CH, Aggarwal M, et al, Mitochondrial dysfunction in multiple system atrophy (2009)

Brodacki B, Staszewski J, Toczyłowska B, et al, Serum inflammatory cytokines in Parkinson's disease and multiple system atrophy (2008)

Bés A, Guisset C, Oertel WH, Neuroinflammation in multiple system atrophy (2010)

Villa C, Colombo G, Menach K, et al, Cyclooxygenase-2 in brain tissue of patients with multiple system atrophy (2009)

Schwarz SC,Seufferlein T,LeWitt PA, et al, Gene expression profiling in multiple system atrophy (2008)

Jellinger KA, Neuropathology of multiple system atrophy (1999)

Matsusue E, Kinoshita T, Sugii Y, Ohama E, Oguri T, Cerebellar pathology in multiple system atrophy: a comparative MRI study (2009)

Courtney E, AM K, Shapiro C, Singer W, Autonomic failure in multiple system atrophy (2009)

Riku Y, Watanabe H, Atsumi N, et al, The "hot cross bun" sign in multiple system atrophy: a comparative MRI study (2009)

Shiga K, Yamada M, Yoshikawa H, et al, MRI characteristics of the middle cerebellar peduncle in multiple system atrophy (2005)

Eckert T, Tang C, Ma Y, et al, Metabolic brain networks in multiple system atrophy: a comparative study with FDG-PET (2008)

Varrone A, Marek KL, Jennings D, et al, Striatal and cortical dopamine transporter binding in multiple system atrophy (2009)

Holmberg B, Johansson JO, Seth H, et al, Cerebrospinal fluid tau in multiple system atrophy (2001)

Fussi N, Schlörer M, Herath P, et al, Cerebrospinal fluid biomarkers in multiple system atrophy: a comparative analysis (2018)

Singer W, Schmeichel AM, Shahnawaz N, et al, Neurofilament light chain as a biomarker in multiple system atrophy (2015)

Kirchhof K, Apostolidou AN, Fowler CJ, Bladder dysfunction in multiple system atrophy: a review (2010)

Wenning GK, Tison F, Yancheva S, et al, The Movement Disorder Society criteria for the diagnosis of multiple system atrophy (2009)

Wenning GK, Geser F, Krismer F, et al, The natural history of multiple system atrophy: a prospective European study (2013)

Fanciulli A, Wenning GK, How to diagnose and treat multiple system atrophy (2015)

Low PA, Singer W, Managing autonomic dysfunction in multiple system atrophy (2008)

Wegrzynowicz M, Bar-On D, Calo L, et al, Deposition of antibodies in brain of patients with multiple system atrophy (2019)

Wagner J, Ryazanov S, Leonov A, et al, Anle138b: a novel small molecule that blocks alpha-synuclein aggregation and ameliorates disease in models of multiple system atrophy (2013)

Junn E, Lee KW, Jeong BS, et al, Repression of alpha-synuclein expression and toxicity in model systems by microRNA-7 (2009)

Beal MF, Neuroprotective effects of coenzyme Q10 in neurodegenerative diseases (2010)

Duyckaerts C, Sazdovitch V, Ando K, et al, Neuroinflammation, microglial activation, and tau pathology in multiple system atrophy (2009)

Song CH, Choi KS, Yu J, Stem cell therapy in multiple system atrophy (2015)

Fornai F, Longone P, Ferrucci M, et al, Lithium delays progression of amyotrophic lateral sclerosis (2008)

Kamei K, Tanaka A, Awata T, et al, Potential disease-modifying effects of statins in multiple system atrophy (2008)

Lee HJ, Bae EJ, Jang EH, et al, Overexpression of alpha-synuclein in oligodendrocytes leads to demyelination (2010)

Kahle PJ, Neumann M, Ozmen L, et al, Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes (2012)

Messmer K, Ravid R, Forman MS, Alpha-synuclein accumulation in oligodendrocytes in multiple system atrophy (2012)

Stefanova N, Tison F, Reindl M, Poewe W, Wenning GK, Animal models of multiple system atrophy (2015)

Dickson DW, Ahmed Z, Hassan A, et al, Neuropathology and biomarkers of progressive supranuclear palsy and corticobasal degeneration (2010)

Peng C, Gathagan RJ, Lee VM, Distinct alpha-synuclein strains and implications for neurodegeneration in multiple system atrophy (2019)

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, et al, Alpha-synuclein and tau in cerebrospinal fluid as biomarkers of multiple system atrophy: a comparative study (2011)

Sydow O, Van Laar T, Van De Giessen A, Gene expression profiling in multiple system atrophy (2009)

Poewe W, Seppi K, Marconi R, et al, Efficacy of intravenous immunoglobulin in the treatment of autoimmune autonomic failure: a randomized controlled trial (2010)

📖 View canonical wiki page →

Related Entities

mechanisms-msa-pathway

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-msa-pathway
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-94f5dc502dd4
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-msa-pathway'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

52

Outgoing

60

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Multiple System Atrophy (MSA) Pathway

Multiple System Atrophy (MSA) Pathway

Overview

Pathway Diagram

Multiple System Atrophy (MSA) Pathway

Overview

Pathway Diagram

Epidemiology and Clinical Presentation

Prevalence and Demographics

Clinical Subtypes

Autonomic Dysfunction

Sleep Disorders

Neuropathology

Glial Cytoplasmic Inclusions

Neuronal Loss and Gliosis

Myelin Pathology

Molecular Pathogenesis

Alpha-Synuclein Aggregation

Mitochondrial Dysfunction

Neuroinflammation

Dysregulation of Myelin Genes

Neuroanatomical Circuits Affected

Basal Ganglia Circuit

Cerebellar Circuit

Autonomic Networks

Biomarkers and Diagnostic Markers

Imaging Biomarkers

Cerebrospinal Fluid Biomarkers

Autonomic Testing

Disease Progression

Clinical Trajectory

Stages of Disease

Therapeutic Targets and Drug Development

symptomatic Treatments

Disease-Modifying Approaches

Repurposing Opportunities

Animal Models

Transgenic Models

Toxin Models

Comparison with Related Disorders

MSA vs. Parkinson's Disease

MSA vs. Progressive Supranuclear Palsy

Research Gaps and Future Directions

Critical Unanswered Questions

Emerging Research Areas

Clinical Trial Landscape

See Also

External Links

References

💬 Discussion